Merck & Co.
AWARDS
NEWS
The U.S. FDA Oncologic Drugs Advisory Committee voted against recommending the drug as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy after surgery, at least for now.
It was a busy week for clinical trial updates. Here’s a look.
A new report shows Merck’s anti-baldness drug Propecia (finasteride) has been linked to more than 700 incidences of suicide and suicidal thoughts, side effects that both Merck and U.S. regulators allegedly knew about since 2011.
Merck Chief Executive Officer Kenneth C. Frazier is stepping down from his role atop the helm of the pharma giant on June 30 after nearly 30 years with the company.
Adding Yervoy to the therapy did not improve overall survival (OS) or progression-free survival (PFS) but did add toxicity to Keytruda monotherapy.
February is kicking off with a number of PDUFA dates for the U.S. FDA as well as a cancer advisory committee meeting. Here’s a look.
JOBS
IN THE PRESS